Background: The up-regulation of PD-L1 is recognized as an adaption of cancer cells to
evade immune surveillance and attack. However, the intrinsic mechanisms of the induction …

Patients with triple-negative breast cancers (TNBC) are at high risk for recurrence and
metastasis at an early time despite standard treatment, underscoring the need for novel …

ABSTRACT UBR5 is a nuclear phosphoprotein of obscure functions. Clinical analyses
reveal that UBR5 amplifications and overexpression occur in over 20% cases of human …

Triple-negative breast cancer (TNBC) is an invasive tumor with a high incidence of distant
metastasis and poor prognosis. In TNBC cells, high PD-L1 expression can induce an …

Background Triple-negative breast cancer is characterized by a poor prognosis and lack of
targeted treatments, and thus, new targeting markers and therapeutic strategies are urgently …

Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been
established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less …

Programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1)
interaction exerts a vital role in tumor-associated immune evasion. While strategies …

Background Triple negative breast cancer (TNBC) is an immunogenically hot tumor. The
immune checkpoint blockades (ICBs) have been recently emerged as promising therapeutic …

Background Recently genome-based studies revealed that the abnormality of Hippo
signaling is pervasive in TNBC and played important role in cancer progression. RING finger …

Background Triple-negative breast cancer (TNBC) remains difficult to be targeted. SET and
cancerous inhibitor of protein phosphatase 2A (CIP2A) are intrinsic protein-interacting …